<DOC>
	<DOCNO>NCT00213564</DOCNO>
	<brief_summary>The objective study identify validate predictive marker infliximab responsiveness RA patient 2 approach : ) measure biochemical , immunological bone marker sera involvement pathogenic mechanism ; ii ) identify gene-expression signature PBMCs transcriptomic analysis . Patients active RA ( ACR criterion ) give i.v . 3 mg/kg infliximab associate metotrexate week 0 , 2 , 6 , every 8th week . Infliximab efficacy evaluate week 14 , use EULAR response criterion . 1 . Just start infliximab treatment , follow parameter measure serum : ) immunological test : rheumatoid factor ( IgA , IgG , IgM ) , anti-CCP , autoAb recognize 27 C-terminal fragment ( ACAST-C27 ) domain I ( ACAST-DI ) calpastatin , anti-G6PI , anti a-enolase , anti-keratin anti-perinuclear factor ; ii ) biochemical marker : CRP , MMP-1 , MMP-3 , TIMP-1 , TIMP-2 ; marker bone resorption : pyridinolin , deoxypyridinolin , osteoprotegerin , sRANKL , COMP . The predictive value parameter response/non-response infliximab analyse use Fischer 's exact , Mann-Whitney Chi2 test . 2 . A blood sample collect onset infliximab treatment total RNAs extract peripheral blood mononuclear cell . The [ 33P ] radiolabeled mRNAs hybridize ( duplicate triplicate ) set 10.000 human cDNA probe spot high density nylon membrane . Data normalize filter allow comparison RNA sample . Statistical analysis perform R software hierarchical clustering perform Cluster Tree View software .</brief_summary>
	<brief_title>Gene Expression Profiling PBMCs Tool Prediction Infliximab Responsiveness Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Is age 18 year old old Satisfies 1987 American College Rheumatology revise criterion Rheumatoid arthritis Has active disease time randomization indicate DAS28 &gt; 5.1 Has disease least refractory DMARDs whose methotrexate leflunomide Is capable understand signing informed consent form Agrees use medically accept form contraception study Is pregnant breastfeed without Has significant concurrent medical disease include cancer history cancer within 5 year enter study , uncompensated congestive heart failure , significant active infection underlying disease could predispose subject infection ( whose tuberculosis ) Has allergy infliximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>